This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
HIV/AIDS	Fas ligand (TNF superfamily, member 6) (FASL)	<p>Studies in macaques suggest that anti-FASL antibodies could preserve vaccine-induced immunity to HIV during the initial stages of infection. Macaques were immunized with a gag-based SIV vaccine and treated with an anti-FASL antibody. Following challenge with SIV, antibody-treated macaques had a better immune response and better survival than untreated controls. Ongoing work includes investigating the role of Fas receptor and FASL in macaque models of chronic SIV infection.</p> <p>Targeted Genetics Corp's tgAAC09, an adeno-associated virus (AAV) HIV vaccine, has completed a Phase II trial.</p> <p>SciBX 2(24); doi:10.1038/scibx.2009.978 Published online June 18, 2009</p>	Unpatented; unlicensed	<p>Poonia, B. <i>et al. Blood</i>; published online June 4, 2009; doi:10.1182/blood-2009-02-202655 Contact: C. David Pauza, Institute of Human Virology, Baltimore, Md. e-mail: cdpauza@ihv.umaryland.edu</p>